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Review Article

Acute pulmonary embolism: endovascular therapy
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Abstract: Pulmonary embolism (PE) is a leading cause of morbidity and mortality worldwide. PE is
a complex disease with a highly variable presentation and the available treatment options for PE are
expanding rapidly. Anticoagulation (AC), systemic lysis, surgery, and catheter-directed thrombolysis (CDT)
play important roles in treating patients with PE. Thus, a multidisciplinary approach to diagnosis, risk
stratification, and therapy is required to determine which treatment option is best for a given patient with
this complex disease.
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Introduction
Pulmonary embolism (PE) is a leading cause of morbidity
and mortality worldwide. The incidence of PE is
approximately 600,000 cases annually with approximately
100,000–180,000 deaths related to PE (1). PE is the most
preventable cause of death among hospitalized patients (2).
Multidisciplinary management of PE
PE is a complex disease with a highly variable presentation.
The available treatment options for PE are expanding
rapidly. Traditionally, the initial evaluating physician
consulted a specialist at his or her discretion. However,
the expansion of therapeutic options and strategies,
spanning multiple specialties, means that no one specialty
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can claim an exclusive or comprehensive domain over the
management of PE.
Recognizing this, many institutions have created
multidisciplinary pulmonary embolism response teams
(PERTs) (3). The PERT model has been described as
a combination of rapid response teams that respond to
critically ill patients immediately and heart teams that
leverage input from a multidisciplinary team to make
clinical decisions on complex patients (4). The functions of
a PERT are to respond rapidly to a request for assistance,
evaluate the patient, form a consensus treatment plan,
and execute it (5). The composition of a PERT can vary,
but PERTs often include physicians from cardiology,
pulmonary/critical care, interventional radiology, cardiac
surgery, hematology, and vascular medicine (6-8).
When a PERT receives a consult, a designated member
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Table 1 AHA definitions of massive, submassive, and low-risk PE and associated mortality (10)
PE classification

Definition

Mortality

Massive

Acute PE with sustained hypotension (< 90 mmHg systolic) >15 minutes
or requiring inotropic support

25–65% (11)

Submassive

Systolic pressure >90 mmHg and either: (I) RV dysfunction
(CT, BPN/proBNP, ECG changes) or (II) myocardial necrosis (elevated troponins)

3% (12)

Low risk

Absence of hypotension, RV dysfunction, and myocardial necrosis

<1% (12)

PE, pulmonary embolism; RV, right ventricular; CT, computed tomography; BPN, B-type natriuretic peptide; ECG, electrocardiography;
AHA, American Heart Association.

of the team will evaluate the patient and review imaging
and lab results. This person will risk stratify the patient
and assess the risk of bleeding. The rest of the team will
convene either in person, via telephone, or via Health
Insurance Portability and Accountability Act (HIPAA)
compliant virtual meeting software. The evaluating team
member will present the case to the group, and the team
members will discuss the case and formulate a treatment
plan. The plan will be shared with the referring physician
as resources are mobilized (i.e., cath lab or OR for
intervention or emergency medical services for inter-facility
transport) (5,8,9).
The PERT model is relatively new, but several existing
PERTs have begun to publish on their initial experiences
(6,7,9). Though data is scant at present, the PERT model
has the potential to effectively streamline care and provide an
evidence-based approach towards management of severe PE.
Risk stratification
Risk stratification guidelines have been developed based on
short term mortality and clinical deterioration. The 2011
American Heart Association’s (AHA) Scientific Statement
for venous thromboembolism management separates
patients into low-risk PE, submassive PE and massive PE
(Table 1) (12). Low-risk PE patients are normotensive
[systolic blood pressure (BP) ≥90 mmHg], have no
right ventricular (RV) dysfunction, and no evidence of
myocardial necrosis. Low-risk PE patients represent
55% of the PE population and have an excellent
prognosis. Massive PE patients have sustained
hypotension (systolic BP <90 mmHg for ≥15 minutes),
require inotropic support, and/or have persistent profound
bradycardia (HR <40 beats per minute with signs or
symptoms of shock). Massive PE patients represent 5% of
the PE population and have a 58% mortality risk (13).
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Defining the submassive/intermediate risk PE
population is more difficult given the broad range of clinical
presentations and the wide mortality range reported in
the literature. Submassive PE patients represent 25–40%
of the PE population with a mortality risk ranging
from 2–3% to 21% at 3 months (13,14). According
to the AHA risk stratification statement, submassive
PE patients are systemically normotensive (systolic
BP ≥90 mmHg) but have evidence of RV dysfunction and/or
myocardial necrosis. RV dysfunction is defined as an
RV/left ventricular (LV) ratio of >0.9 on CT scan or
echocardiogram (Figure 1). Myocardial necrosis is defined
by a B-type natriuretic peptide (BNP) or troponin elevation.
In addition, patients may have electrocardiography (ECG)
changes such as new right bundle branch block (RBBB),
anteroseptal systemic thrombolysis (ST) elevation or
anteroseptal T-wave inversion.
Given the broad range of clinical presentations of
submassive PE patients, the 2014 European Society of
Cardiology (ESC) Guidelines further delineate submassive/
intermediate patients into low and high risk (15,16). The
stratification is dependent on a simplified pulmonary
embolism severity index (sPESI) score. Intermediate-low
risk patients have an sPESI of one or more with either RV
dilation on imaging (echo or CT) or biomarker elevation,
or neither of these. Intermediate-high risk patients have a
sPESI of one or more with RV dilatation on echo/CT and
biomarker elevation.
Systemic and catheter directed lysis
Rationale for thrombolysis
Anticoagulation (AC) alone does not dissolve thrombus.
Rapid restoration of pulmonary perfusion using
thrombolytics can benefit select patients. However,
determining which patients benefit from thrombolysis
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Figure 1 CTA and echocardiogram demonstrating an enlarged right ventricle in a patient with submissive PE. (A) Axial slice CT in a
patient with submassive PE with right ventricle measuring 5.1 cm and left ventricle measuring 2.9 cm. Interventricular septal straightening
and filling defects within both lower lobe pulmonary arteries is also noted; (B) short axis view from an echocardiogram in another patient
demonstrating marked right ventricular dilatation. CT, computed tomography; PE, pulmonary embolism.

is challenging, as outcomes vary substantially depending
on patient characteristics (13). According to the AHA
guidelines, aggressive reperfusion therapy [i.e., ST,
catheter-directed thrombolysis (CDT), and/or surgical
embolectomy] is recommended for massive PE. Such
measures are unnecessary for low-risk PE. However,
clinical judgement is required for submassive PE, as the
decision is not as straightforward (10,12). Furthermore, the
bleeding risk of thrombolytics, discussed below, must also
be considered.
Like the AHA guidelines, the ESC recommends
thrombolytics for high risk PE and AC only for low-risk
PE. Clinical judgement is recommended for intermediate
risk patients. Thrombolytics may be considered for those in
the intermediate-high risk category who are at high risk for
clinical deterioration, whereas AC with close monitoring is
recommended for those with intermediate-low risk PE.
A separate concern is that PE patients are at risk for
long-term functional impairment, shortness of breath, and
decreased quality of life. The elevated pulmonary vascular
resistance and RV pressure due to occlusive thrombus
can damage the RV and subsequently result in decreased
ability to adapt to exercise. A prospective study examined
109 previously healthy patients with first-time submassive PE
treated with AC only (17). At follow-up 6 months after PE,
41% of patients had cardiopulmonary abnormalities: 17%
had only RV dilatation or hypokinesis on echocardiography,
17% had functional limitation as defined by a New York
Heart Association (NYHA) heart failure score > II or a
© Cardiovascular Diagnosis and Therapy. All rights reserved.

6 minutes walk distance <330 meters, and 8% had both.
Additionally, 20% of patients indicated that their quality
of life was worsened by at least one of the following three
indices: diminished health status, inability to shop, or
perceived need for home oxygen. The most severe form
of this condition is chronic thromboembolic pulmonary
hypertension (CTEPH), a condition found in about 4% of
patients at 2-year follow-up, which frequently requires major
surgery (18). However, a higher proportion of patients suffer
chronic disability without resting pulmonary hypertension,
referred to by some as the post-PE syndrome and by others
as chronic thromboembolic disease (CTED) (19).
ST
ST is the administration of a thrombolytic agent through a
peripheral IV. A large systemic dose is required for adequate
delivery of medication to the pulmonary arteries. In the
United States, the Food and Drug Administration (FDA)
approved regimen is the continuous infusion of 100 mg of
alteplase over 2 hours.
ST appears to reduce recurrence or death compared
with AC alone in massive PE (20). As such, thrombolysis
is indicated for massive or high risk PE. In the absence
of hemodynamic instability, such as submassive or
intermediate-risk PE, its use is controversial. There
have been a few randomized clinical trials specifically
investigating the effect of ST and AC vs. AC alone in
submassive PE patients. The 2002 trial by Konstantinides
cdt.amegroups.com
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et al. randomized 256 patients with submassive PE to
100 mg alteplase infusion or heparin alone and found
no difference in mortality, but patients receiving ST less
frequently required treatment escalation (10.2% vs. 24.6%,
P=0.004) (21). The larger and more recent 2014 PEITHO
trial randomized 1,005 patients with intermediate risk
PE to bolus tenecteplase or AC alone and found a lower
rate of death or hemodynamic decompensation in the
tenecteplase group (2.6% vs. 5.6%, P=0.02) (14). However,
overall mortality was not different between the two groups.
Additionally, three meta-analyses examining ST were
completed in 2014. All three showed that, in the setting of
normotensive acute PE, ST reduced the incidence of clinical
deterioration when compared to AC alone (11,22,23). One
of the three studies showed a reduction in overall mortality
that extended to patients with intermediate-risk PE (11).
These short-term clinical improvements are tempered
by the increased risk of major and intracranial bleeding
with ST. The frequency of intracranial hemorrhage
associated with ST is approximately 2% (24). As such,
many patients have contraindications to ST. In the 2014
PEITHO trial, 6.3% of patients in the thrombolysis arm
vs. 1.2% of patients who received placebo experienced
major extracranial bleeding complications (P<0.001) (14).
Additionally, 2.0% of patients receiving thrombolysis
had hemorrhagic stroke vs. 0.2% of those who received
placebo. All three of the 2014 meta-analyses also showed an
increased rate of bleeding complications with ST (11,22,23).
Long-term outcomes after PE may be improved by
initial treatment with ST. In one prospective, observational
study of 162 patients with acute submassive PE who either
received ST or AC alone (25), 27% of the patients who
received AC alone had an RV systolic pressure that was
higher at follow up than baseline, compared with 0% of
the patients who received thrombolysis. Additionally, a
greater proportion of the patients who did not receive
thrombolysis had a NYHA score >2 or 6-minute walk
distance under 330 minutes at 6 months follow-up. The
2013 MOPETT randomized trial of ST vs. AC alone also
showed that patients who received ST had a lower incidence
of pulmonary hypertension, defined as a pulmonary artery
(PA) systolic pressure ≥40 mmHg, at long-term follow-up
(28±5 months) (26).
CDT
Percutaneous catheter-directed methods to remove
pulmonary thrombi include mechanical fragmentation,
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thrombus aspiration, and targeted thrombolytic drug
delivery. CDT is the targeted delivery of a thrombolytic
drug using a multi-sidehole infusion catheter. The side
holes of the catheter are embedded within the thrombus,
maximizing the surface area of thrombus in contact
with the thrombolytic agent. As a result of the targeted
intrathrombus delivery, a much lower dose is required to
achieve clot lysis with CDT vs. ST. A standard regimen is
an infusion rate of 1 mg/hour of alteplase, with 15–30 mg
delivered in total during the course of the treatment.
If two infusion catheters are used, an infusion rate of
0.5 mg/hour/catheter is typical, with the total dose not
to exceed 30 mg. The EkoSonic catheter (BTG, West
Conshohocken, PA, USA) is an alternative infusion catheter
(Figure 2) for directed thrombolysis that contains an
ultrasonic transducer at its core, which is intended to use
sound waves to improve drug penetration into the thrombus
and increase access to fibrin.
Compared to ST, there is a dearth of data regarding
the clinical performance of CDT. There have been three
prospective studies demonstrating that CDT effectively
lyses pulmonary arterial thrombi, improves pulmonary blood
flow at 48 hours, and rapidly restores RV function (27-29).
of the studies had an intracranial hemorrhage. However,
one found that 10% (15/150) of patients who received CDT
experienced major extracranial bleeding complications
requiring transfusion (27). One patient with a groin
hematoma became transiently hypotensive, requiring
vasopressor support. The remainder was normotensive.
There are many unanswered questions regarding
CDT, as the aforementioned prospective studies were
efficacy studies with methodological limitations (10). It is
unclear whether short- and long-term clinical outcomes
are improved and whether it is truly safer than ST. Large
randomized prospective trials are necessary to define CDT’s
optimal use.
Mechanical thrombectomy (MT)
Mechanical fragmentation or MT involves the use of
catheters, suction devices, or other tools to remove or
decrease the clot burden in the pulmonary arteries to
reduce RV afterload and reverse RV failure and shock.
MT may resolve hemodynamic instability in massive PE
patients faster than thrombolytics alone, or may be used
as an adjunct to targeted thrombolytic drug delivery or as
a stand-alone therapy in patients with contraindications to
lytic therapy.
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Figure 2 Successful initiation of bilateral CDT. MIP coronal reconstructions of a contrast-enhanced chest CT demonstrating large occlusive
thrombi (arrowheads) within the right interlobar (A) and left lower lobar (B) arteries; (C) bilateral 5-F 10 cm infusion catheters (UniFuse,
AngioDynamics, Latham, NY, USA) were placed via a right internal-jugular approach and embedded within thrombi. The 10 cm infusion
lengths, where multiple sideholes are present, are demarcated by radiopaque markers (arrowheads). The right-sided catheter is within the
right interlobar artery, and the left-sided catheter is within the left lower lobar artery. CDT, catheter-directed thrombolysis; MIP, maximal
intensity projection; CT, computed tomography.

Indications and patient selection

Thrombectomy devices

MT alone is suggested as a treatment for patients
with massive PE (12) and contraindications to ST.
Contraindications to thrombolysis include active internal
bleeding, recent intracranial or intraspinal surgery or serious
head trauma, intracranial pathology that increases bleeding
risk, bleeding diathesis, and current severe hypertension (30).
Even when screened, the rate of major hemorrhage has been
reported to be as high as 20% in patients receiving ST (31).
MT may also be used when there is insufficient time for
ST to take effect in a hemodynamically unstable patient.
MT may theoretically decrease the amount of thrombolytic
agent required by increasing the surface area exposed to
thrombolytics (32).
A meta-analysis published in 2009 (n=594; 6 prospective
studies, 29 retrospective studies) showed a high success
rate (86.5%) and a low major complication rate (2.4%)
in patients who received MT, with some patients
additionally receiving local thrombolytics, though the
studies comprising the meta-analysis had methodologic
limitations. Several studies have shown that MT combined
with targeted thrombolytic drug delivery may improve
the clinical success rate for massive and sub-massive PE
(28,32,33).

The only percutaneous catheter device that was designed
for and approved specifically for PE intervention was the
Greenfield catheter, a device developed in the 1960s that is
rarely used. Thrombectomy devices that are commonly used
in patients with PE were originally designed for removing
clots from dialysis fistulas or peripheral arteries (34). Since
these devices were designed for use in smaller caliber
vessels than the pulmonary arterial system, the clearance
of thrombus in the pulmonary arteries is not always
achieved (34). There have been multiple retrospective and
prospective trials that have shown preliminary success;
however, these trials have been hampered by small sample
sizes (32). Different strategies for MT include rheolytic
devices (Angiojet, Minneapolis, MN, USA), suction devices,
and fragmentation devices.

© Cardiovascular Diagnosis and Therapy. All rights reserved.

Pigtail catheter
A pigtail catheter can function as a rudimentary MT device.
The catheter is placed over a wire into the PE. The clot can
then be aspirated and agitated to decrease the clot burden
in the central pulmonary arteries. Advantages include wide
availability and low cost (32). In some cases, rotating pigtail
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Figure 3 A 52-year-old female with submassive bilateral PE. Initial right pulmonary angiogram demonstrates a large filling defect in
the interlobar PA (A); fluoroscopic spot image of the Arrow-Trerotola device in the interlobar PA (B); follow-up pulmonary angiogram
demonstrates decrease thrombus in the interlobar artery prior to lysis catheter placement (C). PE, pulmonary embolism; PA, pulmonary artery.

catheter fragmentation has resulted in distal embolization
requiring adjunctive aspiration to correct elevated PA
pressure (35). Despite this risk, fragmentation of the clot
into smaller fragments is typically more hemodynamically
favorable than a large, more proximal occlusion because of
the larger volume of peripheral branches (34,36). A small
meta-analysis (n=121) published in 2007 found that rotation
pigtail catheter thrombectomy in conjunction with local
thrombolytic therapy resulted in a reduction of PA pressure
(33 to 22 mmHg) and a clinical success rate of 95%, with
only 2 instances of major bleeding (33).
Angiojet
The Angiojet (a rheolytic thrombectomy device) injects
pressurized saline or thrombolytic from a catheter into the
thrombus and subsequently aspirates clot via a separate port.
Despite the ease of use and high clinical success rate, there
is a high rate of major complications associated with the
Angiojet system (heart block, hemoglobinuria, temporary
renal insufficiency, major hemoptysis, major hemorrhage, and
procedure related death) (32). In their meta-analysis, Kuo
et al. found a 28% major complication rate in 68 patients who
received Angiojet. Additionally, the release of adenosine from
affected platelets can result in bradycardia and vasospasm.
The bradyarrhythmias caused by adenosine release can
be prevented by administration of glycopyrrolate (37)
or treated by a temporary pacemaker wire. However,
given the high complication rate, Angiojet has a black box
warning from the FDA.

© Cardiovascular Diagnosis and Therapy. All rights reserved.

Rotational thrombectomy
Several rotational thrombectomy devices have potential
uses in the treatment of PE. Most of these devices have
limited descriptions in the literature. First, the ArrowTrerotola percutaneous thrombolytic device (Teleflex
Inc., Morrisville, NC, USA) uses a rotating basket to
break up the clot; as the basket is pulled back, clot can be
withdrawn from the PA. The device comes in an over-thewire version, which uses an 0.025-inch wire, and 6 and
7 Fr versions which are not over the wire and require a
sheath for delivery to the PA (38). Figure 3 demonstrates a
case of submassive PE treated with the Trerotola device in
the right interlobar PA.
Another rotating thrombectomy device that may be
potentially useful in PE is the Cleaner (Argon Medical
Devices, Plano, TX, USA). The Cleaner uses a sinusoidal
rotating wire to disrupt thrombus. It requires delivery via a
6-Fr sheath (39).
Dumantepe et al. describe the use of the Aspirex
Catheter (Straub Medical, Wangs, Switzerland) in 36
patients with massive and submassive PE (40). They were
able to significantly decrease the PA pressures from 53±5.8
to 25.6±6.3 mmHg in patients with massive PE (P<0.01)
and 46±7.7 to 22±3.6 mmHg in patients with submassive
PE (P<0.01) using the Aspirex catheter for rotational
thrombectomy. The devices travels over a 0.018-inch wire
and uses a high-speed rotating spiral located in the body of
the catheter that creates negative pressure through a system
that macerates the thrombus and removes it by aspiration.
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Figure 4 A 67-year-old male with massive PE resulting in PEA arrest underwent emergent thrombectomy with the Penumbra Indigo device
and 4 mg of tPA into the right and left pulmonary arteries. The patient was extubated and discharged from the ICU within 48 hours. (A)
DSA demonstrating thrombus in the right upper lobe PA; (B) Indigo device in the right upper lobe PA; (C) follow-up DSA demonstrates
removal of the thrombus in the right upper lobe PA. PE, pulmonary embolism; ICU, intensive care unit; PEA, pulseless electrical activity;
tPA, tissue plasminogen activator; DSA, digital subtraction angiography; PA, pulmonary artery.

AngioVac
The AngioVac system (AngioDynamics, Latham, NY, USA)
utilizes suction for MT. The system uses a large 26 French
catheter that communicates with the clot and aspirates the
material using suction generated from a system resembling a
cardiopulmonary-bypass circuit. Aspirated clot and blood is
run through a filter, and blood is returned to the circulation.
Pasha et al. published a case report in 2014 detailing the
successful usage of an AngioVac in a woman with an acute
massive PE (41). Generally, however, the AngioVac has
difficulty navigating through the right side of the heart to
the PA due to its bulk and inflexibility (36).

stratification and defined techniques and tools for treating
severe PE. However, data is still insufficient to determine
patient selection for therapeutic escalation, as short term and
long-term efficacy and safety outcomes, especially following
catheter-directed therapies, have not been defined (43).
Additionally, the optimal thrombolytic doses for both ST
and CDT require further evaluation.
Acknowledgements
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Indigo thrombectomy device
The Indigo system (Penumbra Inc., Alameda, CA, USA)
utilizes suction for MT (Figure 4). The device catheter
is inserted into the clot and is directly aspirated; a thin
“separator” at the distal tip of the catheter continuously
breaks up the clot, in order to maintain lumen patency
during aspiration. A small retrospective study (n=6)
published in 2017 found a significant reduction in systolic PA
pressure (58.2 vs. 43.0 mmHg) and RV/LV ratio (1.7 vs. 1.1)
without any complications (42).
Conclusions
Considerable work and research have improved PE risk
© Cardiovascular Diagnosis and Therapy. All rights reserved.
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